Glenmark Recalls Prescription Ranitidine Tablets

Glenmark Pharmaceuticals pulled all unexpired lots of its 150 and 300 mg ranitidine tablets from U.S. shelves, mimicking precautionary measures initiated by Aurobindo, GlaxoSmithKline, Novartis, Sanofi and other drugmakers.

The recall was for possible N-nitrosodimethylamine (NDMA) contamination above the FDA’s acceptable daily intake levels. The carcinogen can cause health problems when ingested in large amounts.

The NDMA contamination issue first came to light last summer, when Chinese API maker Zhejiang Huahai Pharmaceuticals was linked to contaminated valsartan blood pressure drugs.